ClinicalTrials.gg
CompletedNCT04940039CASPARUpdated Apr 27, 2025

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

A Phase 4 interventional study of Risperidone 3 mg and Paliperidone Palmitate 50 mg eq. in Schizophrenia, sponsored by Janssen-Cilag International NV. Completed at 5 sites in Rwanda. Open to participants aged 19 Years to 34 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
19 Years to 34 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
69th of 123
93 · median 100
Started
2021
with 3 others
Phase 4
63 of 127
2 open now
Registered
122nd of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 69th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2021, is one of 63 in phase 4, and was the 122nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 19 Years to 34 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Long-acting injectable antipsychotics
  • Low income countries
  • schizophrenia
04

Who can participate

Ages eligible
19 Years to 34 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in treatment to better address safety, efficacy, or adherence limitations of current treatment
  • Eligible for treatment in the Rwandan mental healthcare system
  • At least moderately ill as measured by the Clinical Global Impression - Severity of Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to [>=] 4). This criterion needs to be re-confirmed at Visit 2
  • Has a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition, provide economic/cost of care information, and is expected to be with the participant for greater than [>] 24 hours each week for the duration of the study)
  • A woman of must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening
  • Able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable (LAI) formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver must sign their own form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Has a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
  • History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
  • Known allergies, , or intolerance to risperidone or paliperidone palmitate or its
  • Received an intervention including investigational vaccines or used an invasive investigational medical device within 30 days before the planned first dose of study intervention, or is currently enrolled in an investigational study
  • Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study intervention
  • Poor prior response to risperidone or paliperidone
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Paliperidone Palmitate

    Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.

    Drug: Risperidone 3 mg · Drug: Paliperidone Palmitate 50 mg eq. · Drug: Paliperidone Palmitate 75 mg eq. · Drug: Paliperidone Palmitate 100 mg eq. · Drug: Paliperidone Palmitate 150 mg eq. · Drug: Paliperidone Palmitate 175 mg eq. · Drug: Paliperidone Palmitate 263 mg eq. · Drug: Paliperidone Palmitate 350 mg eq. · Drug: Paliperidone Palmitate 525 mg eq.

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])

    The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).

    Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

Secondary outcomes

  1. Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

    The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).

    Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

  2. Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)

    The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).

    Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)

  3. Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

    The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.

    Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

  4. Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

    The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.

    Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

  5. Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)

    The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.

    Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)

  6. Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

    The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

  7. Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

    The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

  8. Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)

    The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)

  9. Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

    The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

  10. Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

    The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

  11. Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)

    The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.

    Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)

  12. Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

    The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.

    Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])

  13. Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

    The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.

    Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])

  14. Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)

    The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.

    Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)

  15. Number of Participants with Treatment-emergent Adverse Events

    An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.

    Time frame: Up to Week 66

  16. Number of Participants with Abnormalities in Clinical Laboratory Measures

    Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.

    Time frame: Up to Week 66

  17. Number of Participants with Abnormalities in Vital Signs

    Number of participants with abnormalities in vital signs (temperature \[oral\], pulse/heart rate, and blood pressure) will be reported.

    Time frame: Up to Week 66

  18. Number of Participants with Abnormalities in Electrocardiogram (ECG)

    Number of participants with abnormalities in ECG will be reported.

    Time frame: Up to Week 66

  19. Number of Participants with Abnormalities in Physical Examination

    Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.

    Time frame: Up to Week 66

  20. Number of Participants With Pregnancy Outcome as a Safety Measure

    Number of participants with pregnancy outcome will be reported.

    Time frame: Up to Week 66

  21. Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score

    C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.

    Time frame: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])

07

Study locations

5 sites
  • University Teaching Hospital of Butare(CHUB)
    Butare, NAP, Rwanda
  • Kibuye Referral Hospital
    Kibuye, POBOX44, Rwanda
  • CARAES Ndera Neuro-Psychiatric Hospital
    Kigali, 423, Rwanda
  • University Teaching Hospital of Kigali
    Kigali, KN4, Rwanda
  • Rwamagana Provincial Hospital
    Rwamagana, Rwanda
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2024, 32 months.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2021
First posted
Jun 25, 2021
StartActual
Jul 22, 2021
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04940039
Responsible party
Sponsor
First posted
Jun 25, 2021
Start date
Jul 22, 2021
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Last update
Apr 27, 2025

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risperidone · Paliperidone

Start the discussion